COVID-19 and kidney transplantation

Area of Science:

• Infectious Diseases
• Nephrology
• Immunology

Background:

• The COVID-19 pandemic emerged in March 2020, posing a significant threat to immunocompromised populations, particularly solid organ transplant recipients.
• Transplant centers rapidly adapted protocols to manage patients with SARS-CoV-2 infection and advance understanding of the disease in this vulnerable group.

Purpose of the Study:

• To establish a French Registry for solid organ transplant patients infected with SARS-CoV-2.
• To describe the clinical and biological characteristics of COVID-19 in transplant recipients.
• To identify risk factors and determine the prognosis of COVID-19 in this population.

Main Methods:

• Creation of a national registry collecting data on all solid organ transplant recipients diagnosed with SARS-CoV-2 infection.
• Analysis of registry data to characterize the disease, identify risk factors, and evaluate prognosis.

Main Results:

• The 60-day mortality rate for hospitalized transplant patients with COVID-19 was 23%.
• Renal failure was identified as a significant factor contributing to poor prognosis, alongside known risk factors in the general population.
• Transplant recipients demonstrated suboptimal vaccine responses, necessitating adapted vaccination strategies and continued risk of severe disease.

Conclusions:

• COVID-19 poses a severe risk to solid organ transplant recipients, with renal failure being a critical prognostic indicator.
• Despite vaccination efforts, immunocompromised transplant patients exhibit diminished vaccine efficacy, highlighting the need for specialized preventive and therapeutic strategies.
• The use of enhanced vaccine doses and anti-SARS-CoV-2 monoclonal antibodies are proposed as specific interventions for this high-risk group.